These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27712977)

  • 1. Breast cancer in young women of Chinese Han population: A retrospective study of patients under 25 years.
    Wang W; Wang X; Liu J; Gao J; Wang J; Wang X; Zhao D
    Pathol Res Pract; 2016 Nov; 212(11):1015-1020. PubMed ID: 27712977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component.
    Liao N; Zhang GC; Liu YH; Li XR; Yao M; Xu FP; Li L; Wu YL
    Pathol Res Pract; 2011 Jan; 207(1):1-7. PubMed ID: 21095069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Male breast cancer: a population-based comparison with female breast cancer in Hong Kong, Southern China: 1997-2006.
    Kwong A; Chau WW; Mang OW; Wong CH; Suen DT; Leung R; Wong K; Lee A; Shea C; Morse E; ; Law SC
    Ann Surg Oncol; 2014 Apr; 21(4):1246-53. PubMed ID: 24337541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer in young women from a low risk population in Nepal.
    Thapa B; Singh Y; Sayami P; Shrestha UK; Sapkota R; Sayami G
    Asian Pac J Cancer Prev; 2013; 14(9):5095-9. PubMed ID: 24175782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Family history and risk of ductal carcinoma in situ and triple negative breast cancer in a Han Chinese population: a case-control study.
    Zhou W; Pan H; Liang M; Xia K; Liang X; Xue J; Cheng L; Xue J; Chen S; Liu X; Ding Q; Ling L; Wang S
    World J Surg Oncol; 2013 Oct; 11():248. PubMed ID: 24083544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
    Kim HJ; Han W; Yi OV; Shin HC; Ahn SK; Koh BS; Moon HG; You JH; Son BH; Ahn SH; Noh DY
    Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database.
    Hwang KT; Kim EK; Jung SH; Lee ES; Kim SI; Lee S; Park HK; Kim J; Oh S; Kim YA;
    Breast Cancer Res Treat; 2018 Jun; 169(2):311-322. PubMed ID: 29383628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China.
    Tang LC; Jin X; Yang HY; He M; Chang H; Shao ZM; Di GH
    BMC Cancer; 2015 Mar; 15():201. PubMed ID: 25885213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base.
    Flanagan MR; Rendi MH; Gadi VK; Calhoun KE; Gow KW; Javid SH
    Ann Surg Oncol; 2015 Oct; 22(10):3264-72. PubMed ID: 26202556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy.
    Laird J; Lok B; Siu C; Cahlon O; Khan AJ; McCormick B; Powell SN; Cody H; Wen HY; Ho A; Braunstein LZ
    Ann Surg Oncol; 2018 Jan; 25(1):154-163. PubMed ID: 29094250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival of women with locally advanced breast cancer with ≥ 10 involved lymph nodes at diagnosis.
    Zeichner SB; Cavalcante L; Suciu GP; Ruiz AL; Hirzel A; Krill-Jackson E
    Asian Pac J Cancer Prev; 2014; 15(8):3435-41. PubMed ID: 24870735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer.
    Jung SY; Kim HY; Nam BH; Min SY; Lee SJ; Park C; Kwon Y; Kim EA; Ko KL; Shin KH; Lee KS; Park IH; Lee S; Kim SW; Kang HS; Ro J
    Breast Cancer Res Treat; 2010 Apr; 120(3):627-37. PubMed ID: 20143153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
    Chen Y; Song J; Jiang Y; Yu C; Ma Z
    Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
    Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
    BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.